The announcement seemed, to me, to be a little bit downbeat. Perhaps the efficacy figures were not as good as was first hoped. Perhaps because breast cancer did not get a mention. Perhaps because the trial has been running for so long and SPL staff are a bit jaded and want to move on to newer stuff.
But these results, like cabazitaxel, are very good (and better than I expected).
The most positive aspect for me is the much greater penetration of DEP Docetaxel into the tumours - x10 to x60, proving again that the DEP platform works very well at targeting drugs.
This is a valuable drug with great commercial potential. Let’s hope 2024 brings us the hoped for deals we have been waiting for for so long.
- Forums
- ASX - By Stock
- SPL
- Ann: Positive DEP docetaxel Phase 2 results
Ann: Positive DEP docetaxel Phase 2 results, page-23
-
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.2¢ |
Change
0.002(2.22%) |
Mkt cap ! $37.93M |
Open | High | Low | Value | Volume |
9.2¢ | 9.3¢ | 9.2¢ | $3.349K | 36.18K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 113072 | 9.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.3¢ | 108436 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 113072 | 0.092 |
2 | 161121 | 0.090 |
1 | 6000 | 0.089 |
1 | 127200 | 0.087 |
1 | 6395 | 0.086 |
Price($) | Vol. | No. |
---|---|---|
0.093 | 108436 | 2 |
0.099 | 1285 | 1 |
0.100 | 112106 | 4 |
0.105 | 19523 | 2 |
0.110 | 4000 | 1 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |